ALX Oncology (NASDAQ:ALXO) Trading Up 9.1%

ALX Oncology Holdings Inc. (NASDAQ:ALXO) was up 9.1% during mid-day trading on Tuesday . The stock traded as high as $15.53 and last traded at $15.53. Approximately 205,332 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 430,118 shares. The stock had previously closed at $14.23.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ALXO shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of ALX Oncology in a research note on Friday, April 12th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of ALX Oncology in a research note on Wednesday, April 10th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $14.00 price objective (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.83.

ALX Oncology Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The company has a market capitalization of $843.50 million, a price-to-earnings ratio of -4.50 and a beta of 1.58. The stock has a 50 day simple moving average of $13.61 and a two-hundred day simple moving average of $12.21.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.09). As a group, analysts anticipate that ALX Oncology Holdings Inc. will post -3.33 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Jason Lettmann acquired 4,400 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were bought at an average price of $11.31 per share, with a total value of $49,764.00. Following the completion of the acquisition, the chief executive officer now owns 171,620 shares in the company, valued at approximately $1,941,022.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other ALX Oncology news, insider Jaume Pons sold 50,000 shares of ALX Oncology stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $14.20, for a total value of $710,000.00. Following the sale, the insider now owns 604,205 shares of the company’s stock, valued at approximately $8,579,711. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jason Lettmann acquired 4,400 shares of the stock in a transaction on Thursday, March 14th. The stock was acquired at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the acquisition, the chief executive officer now directly owns 171,620 shares in the company, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. Corporate insiders own 50.30% of the company’s stock.

Institutional Investors Weigh In On ALX Oncology

Institutional investors have recently added to or reduced their stakes in the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in ALX Oncology in the 4th quarter valued at approximately $28,000. China Universal Asset Management Co. Ltd. lifted its position in shares of ALX Oncology by 445.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock valued at $86,000 after acquiring an additional 4,706 shares during the period. SG Americas Securities LLC acquired a new stake in shares of ALX Oncology during the 3rd quarter valued at approximately $48,000. Forefront Analytics LLC acquired a new stake in shares of ALX Oncology during the 3rd quarter valued at approximately $66,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in shares of ALX Oncology during the 4th quarter valued at approximately $215,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.